SYNERA
LOE Approachinglidocaine; tetracaine
NDATOPICALPATCH
Approved
Jun 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNERA is a topical anesthetic patch combining lidocaine and tetracaine for rapid onset, localized skin numbing. It is indicated for use as a topical anesthetic prior to venipuncture or other minor dermatological procedures. The dual local anesthetic formulation works synergistically to provide fast, effective pain relief at the application site.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely focused on lifecycle extension or managed decline strategies, suggesting limited headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYNERA offers limited career growth opportunity given its LOE-approaching status and minimal linked job openings. Roles focus primarily on defensive commercial strategies, cost management, and transition planning rather than growth initiatives.
Brand ManagerTerritory Manager / Field Sales
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.